248 results on '"Nomdedeu, Josep F"'
Search Results
2. Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection
3. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
4. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
5. The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients
6. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
7. Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value
8. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes
9. Supplementary Data from Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
10. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency
11. Genetic determinants of Platelet Large-Cell Ratio, Immature Platelet Fraction, and other platelet-related phenotypes
12. Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes
13. RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRASK117 (TET2/ASXL1)
14. Bone Marrow WT1 mRNA Upregulation in Acute Myeloid Leukemia (AML) in Complete Molecular Remission (mCR): Understanding the Limitations and Advantages of WT1 As a Measurable Residual Disease (MRD) Target
15. Engraftment characterization of risk-stratified AML patients in NSGS mice
16. WT1 monitoring in core binding factor AML: Comparison with specific chimeric products
17. CEBPA bZip mutations: just a single shot
18. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
19. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias
20. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
21. Role of the Polycomb Repressive Complex 2 in Acute Promyelocytic Leukemia
22. The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients
23. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease
24. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
25. Valoración de la mutación V617F del gen JAK2 en síndromes mieloproliferativos crónicos con cromosoma Filadelfia negativo
26. Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)
27. Platelet Ultrastructure in Familial Platelet Disorder with Associated Myeloid Malignancy (FPDMM)
28. FLT3 mutations are associated with other molecular lesions in AML
29. Invisible mycosis fungoides: A diagnostic challenge
30. Invisible mycosis fungoides: A diagnostic challenge
31. Prognostic impact of DNMT3Amutation in acute myeloid leukemia with mutated NPM1
32. Análisis mutacional de p53 en la leucemia linfoblástica T
33. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
34. Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)
35. Adult de novo acute myeloid leukemias with MLL rearrangements
36. Enhanced myeloid specificity of CD 117 compared with CD13 and CD33
37. NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients
38. Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
39. IMPACT OF IMMATURE MARKERS BY FLOW CYTOMETRY IN LEUKEMIC BLAST CELL HETEROGENEITY AML
40. Leading the way in experimental and clinical research in hematology Bone Marrow WT1 Levels In Long-Term Survivors Of Core-Binding Factor AML and Acute Promyelocytic Leukemia
41. Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group
42. Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project
43. Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012
44. Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012
45. Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project
46. Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years
47. R.I.S.C.L: A Holistic Molecular Diagnostic Tool for Myeloid Malignancies
48. The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature
49. Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group
50. Bone Marrow WT1 Levels In Long-Term Survivors Of Core-Binding Factor AML and Acute Promyelocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.